Abstract:

[Abstract] Cardiovascular disease (CVD) is one of the major complications of type 2 diabetes mellitus (T2DM), which results in a high risk of mortality. Thus, the cardiovascular safety of new anti-diabetic agents has become an important problem with wide concern. There are two classes of incretine-based medications: glucagon-like peptide- 1 receptor agonist (GLP-1RA) and dipeptidyl peptidase-4 (DPP-4) inhibitor (DPP-4I). It has been demonstrated that GLP-1RA and DPP-4I possesse beneficial actions in both animal models of cardiovascular dysfunction and patients with ischemic heart diseases. However, their effects on the cardiovascular system in diabetic patients with heart diseases are still uncertain. Here, we sys-tematically reviewed the effects of GLP-1RA and DPP-4I on cardiovascular system to provide more evidence of incretinbased therapy application for diabetes and complications.

Key words: diabetes mellitus, type 2, cardiovascular disease, glucagon-like peptide 1, enzyme dipeptidyl peptidases